Pre-market Hot Trades in US Stocks
Synopsys pre-market rose 5.45%. According to recent important news:
<ol>
<li>
On September 11, Synopsys announced its Q3 financial report, which fell short of expectations, causing the stock price to drop nearly 19% in pre-market trading. The report showed a net profit decline of 43.06% year-on-year, with earnings per share below expectations. Source: DoNews
</li>
<li>
On September 10, Wall Street analysts downgraded Synopsys' rating and target price, with Baird lowering the rating from &#34;Outperform&#34; to &#34;Neutral&#34; and the target price from $670 to $535. Source: Zhitong Finance
</li>
<li>
On September 9, Synopsys announced a global layoff of 10%, intensifying market concerns about its future performance. Source: Jinwu Finance Technology industry faces multiple challenges and requires cautious assessment.
</li>
</ol>
Abbvie pre-market rose 4.04%. According to recent key news:
<ol>
<li>
On September 9, Abbvie reached a global licensing agreement with Glenmark Pharma, paying $700 million for the license of its experimental blood cancer drug ISB 2001, driving the stock price up. Data source: Reuters
</li>
<li>
On September 11, Abbvie reached a settlement with generic drug manufacturers regarding the Uproleselan patent litigation, ensuring that Uproleselan tablets will not face generic competition before April 2037, enhancing market confidence. Data source: SEC filings
</li>
<li>
On September 8, Abbvie's new drugs Skyrizi and Rinvoq saw significant sales growth, offsetting the decline in Humira sales, driving an overall revenue increase of 8% for the company. Data source: Market Observation Biopharmaceutical industry trends are positive, with significant capital inflows.
</li>
</ol>
Top Gainers in Pre-market US Stocks
Silexion Therapeutics pre-market rose 193.20%. Based on recent key news:
<ol>
<li>
On September 11, Silexion Therapeutics announced that its experimental therapy SIL20 showed positive preclinical data in major sites of pancreatic cancer metastasis, including the liver, peritoneum, and lungs, significantly reducing tumor burden. This news drove the stock price up sharply. Data source: Company announcement.
</li>
<li>
On September 11, the company plans to initiate Phase 2/3 clinical trials in the first half of 2026 and aims to make regulatory submissions in Q4 2025 and Q1 2026. This progress has enhanced market confidence. Data source: Company announcement.
</li>
<li>
On September 11, technical analysis indicated a bearish trend for the stock, but due to the company's promising development prospects, especially the collaboration on SIL204 and positive preclinical results, there remains potential for price appreciation. Data source: Technical analysis report. The biotechnology sector has been active recently.
</li>
</ol>
Vince Holdings pre-market rose 146.38%. According to recent key news:
<ol>
<li>
On September 10, Vince Holdings released its second-quarter financial report, with a net income of $12.06 million and earnings per share of $0.93. This strong financial data drove a significant increase in the stock price.
</li>
<li>
On September 10, Vince Holdings' management forecasted that net sales for the third quarter would remain flat or grow by 3%, and they expect adjusted EBITDA margins to be between 2% and 5%. This optimistic outlook further boosted market confidence.
</li>
<li>
On September 10, Vince Holdings' wholesale business showed some weakness, but its direct-to-consumer business achieved growth, partially offsetting the decline in wholesale. This adjustment in business structure also had a positive impact on the stock price. The overall industry performed well, and the macroeconomic environment remained stable
</li>
</ol>

SNPS

ABBV

Synopsys pre-market up 5.45%; Abbvie pre-market up 4.04%; Silexion Therapeutics pre-market up 193.20%; Vince Holdings pre-market up 146.38%; YY pre-market up 90.09%

Pre-market hot trades in US stocks: Synopsys up 5.45% pre-market; Abbvie up 4.04% pre-market